Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- LDP Project Team on Drug Discovery Capabilities Likely to Meet Aug. 4
July 28, 2021
- Label Revisions Ordered for AstraZeneca’s COVID-19 Vaccine; Thrombocytopenia Added to Adverse Reactions
July 28, 2021
- Panels Agree to Add Risk of Thrombocytopenia to AstraZeneca Vaccine Label
July 27, 2021
- Prioritize Alfacalcidol Supply for Non-Osteoporosis Indications: MHLW
July 27, 2021
- Spread of Regional Formularies Will Depend on “Human Relationships and Consensus-Building”: Professor
July 26, 2021
- Chuikyo Reps Fret Negative Impact of Tougher Pledge Rule, but MHLW Says It’s Conducive to Stable Supplies
July 26, 2021
- Chuikyo Roughly Approves 11 Proposals to Hone CEA System
July 26, 2021
- MHLW to Tighten “Written Pledge” Rule on Generic Listings to Thwart Supply Issues
July 26, 2021
- Japan to Discuss Approval of Individual Fertility Drugs after August
July 26, 2021
- Label Revisions Ordered for Evenity, Other Bone Disease Drugs
July 21, 2021
- Wariness Brewing within MHLW for Medical Fee to Incentivize Hospital Formularies
July 21, 2021
- Japan to Receive 50 Million More Doses of Moderna Vaccine
July 21, 2021
- New Generic Target Seems “Conservative Goal”, Dispensing Premium Revision Is a Must: Budget Examiner
July 20, 2021
- Key MOF Official Wants Budget Neutrality, Cap to Optimize Drug Costs
July 20, 2021
- Prefectural Governors Push AstraZeneca Vaccine Use
July 20, 2021
- Japan Approves COVID-19 Antibody Cocktail, 1st Drug for Mild Cases
July 20, 2021
- Takeda’s Pevonedistat Up for Discussion for 1st Legally Backed Sakigake Designation
July 19, 2021
- Lilly’s Selpercatinib, Rinvoq’s Eczema Use Up for PAFSC Review on July 30
July 19, 2021
- Japan Expands Supply of AstraZeneca’s COVID-19 Vaccine to Asian Nations
July 19, 2021
- New Pharma Industry Vision to Set Out Roles of Wholesalers: MHLW Director
July 16, 2021
ページ
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…